scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.SEMCANCER.2013.07.005 |
P698 | PubMed publication ID | 23917255 |
P50 | author | Riccardo Dolcetti | Q37378489 |
Jessica Dal Col | Q59145519 | ||
Antonino Carbone | Q61134450 | ||
Debora Martorelli | Q114435428 | ||
P2093 | author name string | Eva Klein | |
P2860 | cites work | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 |
P433 | issue | 6 | |
P921 | main subject | pathogenesis | Q372016 |
P304 | page(s) | 441-456 | |
P577 | publication date | 2013-08-03 | |
P1433 | published in | Seminars in Cancer Biology | Q1908668 |
P1476 | title | Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas | |
P478 | volume | 23 |
Q38907078 | A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting. |
Q39188257 | BZLF1 Attenuates Transmission of Inflammatory Paracrine Senescence in Epstein-Barr Virus-Infected Cells by Downregulating Tumor Necrosis Factor Alpha |
Q38877813 | Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning |
Q36651583 | Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma. |
Q28077209 | Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis |
Q33846801 | Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. |
Q35808018 | Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma |
Q54221806 | EBV Positive Diffuse Large B Cell Lymphoma and Chronic Lymphocytic Leukemia Patients Exhibit Increased Anti-dUTPase Antibodies. |
Q41168739 | EBV, an inhibited receptor kinase, and lymphoma |
Q51735191 | EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. |
Q37619108 | Epstein-Barr virus and telomerase: from cell immortalization to therapy |
Q39036600 | Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells |
Q52719942 | Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications. |
Q40291554 | Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma |
Q34671009 | HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape |
Q89899110 | Identification and cloning of a new western Epstein-Barr virus strain that replicates efficiently in primary B cells |
Q91315039 | Identification of the Epstein Barr Virus portal |
Q47148419 | Impact of Chronic Viral Infection on T-Cell Dependent Humoral Immune Response |
Q40056807 | Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD. |
Q39281253 | Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. |
Q49590083 | Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. |
Q38568602 | Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma |
Q40089376 | Regulation of Telomere Homeostasis during Epstein-Barr virus Infection and Immortalization. |
Q57176933 | Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target |
Q37603448 | Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells |
Q59355991 | The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control |
Q38212485 | Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? |
Search more.